Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

According to Benzinga Pro, Sarepta Therapeutics's peer group average for short interest as a percentage of float is 12.31%, which means the company has more short interest than most of its peers. Did ...

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...